Skip to content
PeptideTech
Cart

Home / Research library / ARA-290

Peptides

ARA-290: molecular data, studies & sources

ARA-290 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C51H84N16O21
Molecular weight (MW)
1257.3 g/mol
PubChem compound ID
91810664
Record title
Cibinetide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 91810664 · retrieved 2026-09-21

PubChem 2D molecular structure for ARA-290, CID 91810664
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
InChIKey
WZTIQQBMSJTRBR-WYKNNRPVSA-N
SMILES
C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
Machine-readable PubChem source

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

    Heij L, Niesters M, Swartjes M et al. · Molecular medicine (Cambridge, Mass.) · 2012

    PMID 23168581 · DOI: 10.2119/molmed.2012.00332

  2. Human study · PubMed trial index

    ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

    Dahan A, Dunne A, Swartjes M et al. · Molecular medicine (Cambridge, Mass.) · 2013

    PMID 24136731 · DOI: 10.2119/molmed.2013.00122

  3. Human study · PubMed trial index

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

    Brines M, Dunne AN, van Velzen M et al. · Molecular medicine (Cambridge, Mass.) · 2015

    PMID 25387363 · DOI: 10.2119/molmed.2014.00215

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

    van Velzen M, Heij L, Niesters M et al. · Expert opinion on investigational drugs · 2014

    PMID 24555851 · DOI: 10.1517/13543784.2014.892072

  2. Research publication · design requires review

    ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

    Zhang W, Yu G, Zhang M et al. · Peptides · 2016

    PMID 26774587 · DOI: 10.1016/j.peptides.2016.01.003

  3. Preclinical / laboratory research

    Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

    Al-Onaizi MA, Thériault P, Lecordier S et al. · Brain, behavior, and immunity · 2022

    PMID 34343617 · DOI: 10.1016/j.bbi.2021.07.016

  4. Preclinical / laboratory research

    A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

    Watanabe M, Lundgren T, Saito Y et al. · Transplantation · 2016

    PMID 26683514 · DOI: 10.1097/TP.0000000000001026

ARA-290 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Compare all ARA-290 sizes, forms and supplier prices →

SupplierRecorded packagesExample source listing
American PeptidesUSD10mg Vial1 recorded offers10mg Vial · $82.00Checked Sep 21, 2026Supplier listing
Amino ClubUSD10mg Vial1 recorded offers10mg Vial · $49.99Checked Sep 16, 2026Supplier listing
Amino USAUSD10mg Vial · 50mg Vial2 recorded offers10mg Vial · $45.00Checked Sep 16, 2026Supplier listing
Cenexa LabsUSD10mg Vial1 recorded offers10mg Vial · $74.99Checked Sep 16, 2026Supplier listing
AminoVaultUSD10mg Vial1 recorded offers10mg Vial · $68.85Checked Sep 19, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles